Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.

Abstract

PURPOSE:

To determine the pharmacokinetics and skin toxicity profile of sorafenib in children with refractory/relapsed malignancies.

PATIENTS AND METHODS:

Sorafenib was administered concurrently or sequentially with clofarabine and cytarabine to patients with leukemia or with bevacizumab and cyclophosphamide to patients with solid tumor malignancies. The population pharmacokinetics (PPK) of sorafenib and its metabolites and skin toxicities were evaluated.

RESULTS:

In PPK analysis, older age, bevacizumab and cyclophosphamide regimen, and higher creatinine were associated with decreased sorafenib apparent clearance (CL/f; P < 0.0001 for all), and concurrent clofarabine and cytarabine administration was associated with decreased sorafenib N-oxide CL/f (P = 7e-4). Higher bilirubin was associated with decreased sorafenib N-oxide and glucuronide CL/f (P = 1e-4). Concurrent use of organic anion-transporting polypeptide 1B1 inhibitors was associated with increased sorafenib and decreased sorafenib glucuronide CL/f (P < 0.003). In exposure-toxicity analysis, a shorter time to development of grade 2-3 hand-foot skin reaction (HFSR) was associated with concurrent (P = 0.0015) but not with sequential (P = 0.59) clofarabine and cytarabine administration, compared with bevacizumab and cyclophosphamide, and with higher steady-state concentrations of sorafenib (P = 0.0004) and sorafenib N-oxide (P = 0.0275). In the Bayes information criterion model selection, concurrent clofarabine and cytarabine administration, higher sorafenib steady-state concentrations, larger body surface area, and previous occurrence of rash appeared in the four best two-predictor models of HFSR. Pharmacokinetic simulations showed that once-daily and every-other-day sorafenib schedules would minimize exposure to sorafenib steady-state concentrations associated with HFSR.

CONCLUSIONS:

Sorafenib skin toxicities can be affected by concurrent medications and sorafenib steady-state concentrations. The described PPK model can be used to refine exposure-response relations for alternative dosing strategies to minimize skin toxicity.

• Authors: Hiroto Inaba, John C Panetta, Stanley B Pounds, Lei Wang, Lie Li, Fariba Navid, Sara M Federico, Eric D Eisenmann, Aksana Vasilyeva, Yong-Dong Wang, Sheila Shurtleff, Ching-Hon Pui, Tanja A Gruber, Raul C Ribeiro, Jeffrey E Rubnitz, Sharyn D Baker
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 25 Issue 24 Pg. 7320-7330 (12 15 2019) ISSN: 1557-3265 [Electronic] United States
• PMID: 31455680 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: ©2019 American Association for Cancer Research.

Chemical References

• Cytarabine
• Bevacizumab
• Clofarabine
• Cyclophosphamide
• Sorafenib

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, pharmacokinetics)
• Bevacizumab (administration & dosage)
• Child
• Clofarabine (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Cytarabine (administration & dosage)
• Drug Resistance, Neoplasm (drug effects)
• Humans
• Leukemia (drug therapy, pathology)
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Neoplasms (drug therapy, pathology)
• Skin Diseases (chemically induced, pathology)
• Sorafenib (administration & dosage)
• Tissue Distribution
• Young Adult